Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Eli Lilly and Company (LLY - Analyst Report) and partner Boehringer Ingelheim are facing an issue related to Jardiance (empagliflozin) in the UK. The National Institute for Health and Care Excellence (NICE) has requested for additional information to validate that Jardiance is cost-effective in comparison with other treatment options already available in the market.
Jardiance was approved in Europe in May 2014 to improve glycemic control in adults suffering from type II diabetes.
The price of Jardiance, according to the press release, stands at £36.59 (excluding VAT) per pack of 28 tablets (10 mg and 25 mg doses). The estimated annual cost of the drug is £470.30. However, the cost might vary depending on negotiations and procurement discounts.
http://www.zacks.com/stock/news/145672/eli-lilly-boehringer-drugs-cost-effectiveness-questioned
Jardiance was approved in Europe in May 2014 to improve glycemic control in adults suffering from type II diabetes.
The price of Jardiance, according to the press release, stands at £36.59 (excluding VAT) per pack of 28 tablets (10 mg and 25 mg doses). The estimated annual cost of the drug is £470.30. However, the cost might vary depending on negotiations and procurement discounts.
http://www.zacks.com/stock/news/145672/eli-lilly-boehringer-drugs-cost-effectiveness-questioned